AUTHORS
Santosh L Saraf, MD, Sheinei Alan, MD, PhD2, Kelly A Fader, PhD3, Yuvika Paliwal, N/A4, Denis Rybin, N/A5, Frank E Plonski, BS, ASN, MA6, Geoffrey Allen, MD7, Modupe Idowu, MD8
AFFILIATIONS
1 University of Illinois Chicago, Chicago, Illinois, United States
2 Inova Schar Cancer Institute, Fairfax, Virginia, United States
3 Pfizer Inc., Groton, Connecticut, United States
4 Pfizer Inc., New York, New York, United States
5 Pfizer Inc., Cambridge, Massachusetts, United States
6 Pfizer Inc., Collegeville, Pennsylvania, United States
7 Pfizer Inc., Collegeville, Pennsylvania, United States
8 University of Texas Health McGovern Medical School, Houston, Texas, United States
ABSTRACT
Introduction
Sickle cell disease (SCD) is characterized by polymerization of hemoglobin S (HbS), causing red blood cells (RBCs) to become rigid and sickle, leading to chronic hemolytic anemia. Episodes of severe ischemic pain, known as vaso-occlusive crises (VOCs), are triggered when the rigid, sickled RBCs block small blood vessels, depriving surrounding tissues of oxygen. Osivelotor is a small-molecule HbS polymerization inhibitor being investigated as a potential treatment for SCD. Previous studies in participants with SCD have demonstrated osivelotor is generally well tolerated, and treatment is associated with increases in Hb concentration and reductions in markers of hemolysis. Reduced numbers of sickled cells, increased RBC deformability, and improvements in markers of microvascular blood flow have also been reported. These changes, together with the observed normalization of whole blood viscosity due to Hb increases, are hypothesized to reduce the risk of VOCs. Exploratory analyses of the osivelotor phase 2 study and open-label extension (OLE) supported this hypothesis, showing a decrease in the annualized rate of VOC despite substantial Hb increases. To provide further insight, this post hoc analysis evaluated the relationship between change in Hb concentration and the rate of VOCs.
Methods
Data were analyzed from the phase 2 part of an ongoing multicenter, phase 2/3 trial (NCT05431088) and OLE (NCT05632354). The phase 2 study was an open-label dose-finding study in adults with SCD (HbSS/HbSβ0 genotype) and a screening Hb concentration of 5.5–10.5 g/dL. At screening, VOC history in the past 12 months was collected. Participants were randomized to osivelotor 100 or 150 mg once-daily groups for 12 weeks. Eligible participants completing Week 12 could enter the OLE; this analysis included OLE data up to Week 108. In both studies, VOCs were recorded at all study visits and Hb was evaluated in central laboratories. As prior osivelotor data show maximal Hb increase is reached after ~4–6 weeks and generally maintained thereafter, we defined steady-state on-treatment Hb as the mean of values from Week 6 of the phase 2 study to Week 108 of the OLE. The annualized VOC rate was considered unchanged if the number of VOCs per year increased by ≤1 or decreased by ≤1. Analyses included all participants in the 100 or 150 mg osivelotor groups who received ≥1 study drug dose and had Hb measurements available at baseline and Week 6 of the phase 2 study. The relationship between Hb concentration and VOCs was evaluated with a negative binomial regression model, using an offset to adjust for follow-up differences. The effect of baseline disease severity was also assessed by adjusting the model for baseline Hb and VOCs in the year pre-screening.
Results
In total, 53 participants in the osivelotor 100 or 150 mg groups were included in this analysis. Baseline Hb values ranged from 6.2 to 11.2 g/dL, and 22 participants had baseline Hb ≤8.0 g/dL. Treatment duration across the phase 2 study and OLE ranged from 0.2 to 2.0 years, and average steady-state on-treatment Hb values ranged from 6.8 to 15.5 g/dL. During the year pre-screening, the annualized rate of VOCs ranged between 0 and 6 events per year with 13 of 53 participants having no VOCs during the year pre-screening. The annualized rate of VOCs on treatment ranged between 0 and 9.5 events per year, with 20 participants having a rate decrease of >1 VOC per year, 8 participants having an increase of >1 VOC per year, and 25 had no change. Overall, large changes in Hb were not associated with an increased VOC rate, and no pattern was apparent for subgroups with baseline Hb above or below 8 g/dL. Further, when a negative binomial regression model was fitted to this data adjusted for baseline disease severity (baseline VOC rate and baseline Hb value), larger Hb increase from baseline was associated with a reduced annualized VOC rate on treatment (rate ratio 0.64; 95% confidence interval 0.46, 0.89; P=0.007).
Conclusions
In patients with SCD receiving osivelotor, larger changes in Hb concentration were not associated with increased rates of VOCs, regardless of baseline Hb levels. Sizeable Hb increases were associated with apparent decreases in VOC. These post hoc analyses require confirmation, and the ongoing phase 3 study of osivelotor will provide a more robust assessment of VOCs over 48 weeks of treatment, with VOCs adjudicated by a blinded, independent expert panel.
DISCLOSURES
Santosh L Saraf, MD: Novartis - Research Funding; Pfizer - Research Funding; Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BEAM Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Chiesi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)